Cargando…

Antithyroid drugs in Graves’ disease: Are we stretching it too far?

INTRODUCTION: Early and durable achievement of euthyroid or hypothyroid status with low likelihood of relapse is the key to effective treatment of Graves’ disease (GD). Although antithyroid drugs (ATDs) are commonly used first-line agents, likelihood of remission remains highest with radioactive iod...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayaraman, Muthukrishnan, Pawah, Anil Kumar, Narayanan, C. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040037/
https://www.ncbi.nlm.nih.gov/pubmed/27730067
http://dx.doi.org/10.4103/2230-8210.190525
_version_ 1782456175165440000
author Jayaraman, Muthukrishnan
Pawah, Anil Kumar
Narayanan, C. S.
author_facet Jayaraman, Muthukrishnan
Pawah, Anil Kumar
Narayanan, C. S.
author_sort Jayaraman, Muthukrishnan
collection PubMed
description INTRODUCTION: Early and durable achievement of euthyroid or hypothyroid status with low likelihood of relapse is the key to effective treatment of Graves’ disease (GD). Although antithyroid drugs (ATDs) are commonly used first-line agents, likelihood of remission remains highest with radioactive iodine (RAI) therapy and surgery. Data regarding efficacy and economical superiority of RAI therapy over ATDs are lacking from India. This study was designed to study the response to long-term (>12 months) use of ATDs in GD with respect to attainment of remission and to compare the cost of treatment with ATDs versus RAI therapy beyond 12 months. SETTINGS: The study was conducted in a tertiary care center. STUDY DESIGN: This was a retrospective analysis. MATERIALS AND METHODS: Patients of GD in our follow-up from February 2009 to March 2016 who had received ATDs for a duration exceeding 12 months were retrospectively analyzed. Patients who underwent radioablation after a period of at least 12 months on ATDs were analyzed and their status was recorded after a minimum of 6 months after radioablation. Patients who remained hyperthyroid beyond 12 months and received RAI therapy were further compared with those who continued on ATDs, for achievement of euthyroid or hypothyroid status. Cost analysis was done for follow-ups and treatment and compared. STATISTICAL ANALYSIS USED: All analyses were done using Fisher's exact test for categorical and descriptive statistics for numerical data. RESULTS: Use of ATDs leading to euthyroid and hypothyroid status in GD patients was only significant beyond 24 years when compared to those at <12–18 months therapy (P = 0.0262 and P = 0.0217, respectively). The patients who ended up with hypothyroid status were significantly greater in RAI group compared to ATD group (P = 0.0003). Cost of therapy per patient beyond 12 months was lower in the RAI group compared to the ATD group (cost difference Rs. 5435.00). CONCLUSIONS: Within limitations, our study demonstrates that RAI is effective and economical option in GD.
format Online
Article
Text
id pubmed-5040037
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-50400372016-10-11 Antithyroid drugs in Graves’ disease: Are we stretching it too far? Jayaraman, Muthukrishnan Pawah, Anil Kumar Narayanan, C. S. Indian J Endocrinol Metab Original Article INTRODUCTION: Early and durable achievement of euthyroid or hypothyroid status with low likelihood of relapse is the key to effective treatment of Graves’ disease (GD). Although antithyroid drugs (ATDs) are commonly used first-line agents, likelihood of remission remains highest with radioactive iodine (RAI) therapy and surgery. Data regarding efficacy and economical superiority of RAI therapy over ATDs are lacking from India. This study was designed to study the response to long-term (>12 months) use of ATDs in GD with respect to attainment of remission and to compare the cost of treatment with ATDs versus RAI therapy beyond 12 months. SETTINGS: The study was conducted in a tertiary care center. STUDY DESIGN: This was a retrospective analysis. MATERIALS AND METHODS: Patients of GD in our follow-up from February 2009 to March 2016 who had received ATDs for a duration exceeding 12 months were retrospectively analyzed. Patients who underwent radioablation after a period of at least 12 months on ATDs were analyzed and their status was recorded after a minimum of 6 months after radioablation. Patients who remained hyperthyroid beyond 12 months and received RAI therapy were further compared with those who continued on ATDs, for achievement of euthyroid or hypothyroid status. Cost analysis was done for follow-ups and treatment and compared. STATISTICAL ANALYSIS USED: All analyses were done using Fisher's exact test for categorical and descriptive statistics for numerical data. RESULTS: Use of ATDs leading to euthyroid and hypothyroid status in GD patients was only significant beyond 24 years when compared to those at <12–18 months therapy (P = 0.0262 and P = 0.0217, respectively). The patients who ended up with hypothyroid status were significantly greater in RAI group compared to ATD group (P = 0.0003). Cost of therapy per patient beyond 12 months was lower in the RAI group compared to the ATD group (cost difference Rs. 5435.00). CONCLUSIONS: Within limitations, our study demonstrates that RAI is effective and economical option in GD. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5040037/ /pubmed/27730067 http://dx.doi.org/10.4103/2230-8210.190525 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Jayaraman, Muthukrishnan
Pawah, Anil Kumar
Narayanan, C. S.
Antithyroid drugs in Graves’ disease: Are we stretching it too far?
title Antithyroid drugs in Graves’ disease: Are we stretching it too far?
title_full Antithyroid drugs in Graves’ disease: Are we stretching it too far?
title_fullStr Antithyroid drugs in Graves’ disease: Are we stretching it too far?
title_full_unstemmed Antithyroid drugs in Graves’ disease: Are we stretching it too far?
title_short Antithyroid drugs in Graves’ disease: Are we stretching it too far?
title_sort antithyroid drugs in graves’ disease: are we stretching it too far?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040037/
https://www.ncbi.nlm.nih.gov/pubmed/27730067
http://dx.doi.org/10.4103/2230-8210.190525
work_keys_str_mv AT jayaramanmuthukrishnan antithyroiddrugsingravesdiseasearewestretchingittoofar
AT pawahanilkumar antithyroiddrugsingravesdiseasearewestretchingittoofar
AT narayanancs antithyroiddrugsingravesdiseasearewestretchingittoofar